1. Molecular mechanisms related to responses to oxidative stress and antioxidative therapies in COVID-19Evangelia Eirini Tsermpini, Una Glamočlija, Fulden Ulucan-Karnak, Sara Redenšek Trampuž, Vita Dolžan, 2022, review article Keywords: COVID-19, oxidative stress, genetics, antioxidant enzymes, anti-oxidative therapies, glutathione, N-acetylcysteine
Full text (file, 2,25 MB) This document has more files! More... |
|
3. Serotonin-related functional genetic variants affect the occurrence of psychiatric and motor adverse events of dopaminergic treatment in Parkinson’s diseaseSara Redenšek Trampuž, Tanja Blagus, Maja Trošt, Vita Dolžan, 2022, original scientific article Keywords: Parkinson’s disease, motor complications, visual hallucinations, impulse control disorders, dyskinesia, polymorphism, serotonin, adverse event, pharmacogenomics
Full text (file, 550,02 KB) This document has more files! More... |
4. Clinical and clinical-pharmacogenetic models for prediction of the most common psychiatric complications due to dopamingeric treatment in Parkinson's diseaseSara Redenšek Trampuž, Barbara Jenko Bizjan, Maja Trošt, Vita Dolžan, 2020, original scientific article Keywords: Parkinson's disease, polymorphism, pharmacogenetics, impulse control disorders, predictive model, psychiatric complications, visual hallucinations
Full text (file, 3,37 MB) This document has more files! More... |
5. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's diseaseSara Redenšek Trampuž, Dušan Flisar, Maja Kojović, Milica Gregorič Kramberger, Dejan Georgiev, Zvezdan Pirtošek, Maja Trošt, Vita Dolžan, 2019, original scientific article Keywords: Parkinson's disease, susceptibility, polymorphism, inflammation, oxidative stress, adverse events
Full text (file, 673,75 KB) This document has more files! More... |
6. Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's diseaseSara Redenšek Trampuž, Dušan Flisar, Maja Kojović, Milica Gregorič Kramberger, Dejan Georgiev, Zvezdan Pirtošek, Maja Trošt, Vita Dolžan, 2019, original scientific article Keywords: Parkinson's disease, genetic polymorphism, dopaminergic pathway, personalized medicine, adverse events
Full text (file, 411,70 KB) This document has more files! More... |
7. Assessment of the telomere length and its effect on the symptomatology of Parkinson's diseaseTina Levstek, Sara Redenšek Trampuž, Maja Trošt, Vita Dolžan, Katarina Trebušak Podkrajšek, 2021, original scientific article Keywords: Parkinson's disease, telomere length, levodopa treatment, telomere attrition, dementia
Full text (file, 737,20 KB) This document has more files! More... |
|
9. Genetic variability of the vitamin D receptor affects susceptibility to Parkinson's disease and dopaminergic treatment adverse eventsSara Redenšek Trampuž, Tilen Kristanc, Tanja Blagus, Maja Trošt, Vita Dolžan, 2022, original scientific article Keywords: vitamin D receptor, Parkinson’s disease, biomarker, risk, susceptibility, adverse events, vitamin D, polymorphism
Full text (file, 279,78 KB) This document has more files! More... |
10. Investigation of paraoxonase-1 genotype and enzyme-kinetic parameters in the context of cognitive impairment in Parkinson’s diseaseBoštjan Petrič, Sara Redenšek Trampuž, Vita Dolžan, Milica Gregorič Kramberger, Maja Trošt, Nikola Maraković, Marko Goličnik, Aljoša Bavec, 2023, original scientific article Keywords: Parkinson disease, cognitive impairment, paraoxonase 1, paraoxonase activity, single-nucleotide polymorphisms, iFIT
Full text (file, 1,14 MB) This document has more files! More... |
